Cytokinetics, Incorporated

Equities

CYTK

US23282W6057

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
70.11 USD -1.82% Intraday chart for Cytokinetics, Incorporated +6.18% -16.03%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Cytokinetics, Incorporated(NasdaqGS:CYTK) added to S&P 400 - Biotechnology CI
Cytokinetics, Incorporated(NasdaqGS:CYTK) added to S&P 400 Health Care CI
Cytokinetics, Incorporated(NasdaqGS:CYTK) added to S&P 400 CI
Cytokinetics, Incorporated(NasdaqGS:CYTK) dropped from S&P 600 CI
Cytokinetics, Incorporated(NasdaqGS:CYTK) dropped from S&P 600 Health Care CI
Transcript : Cytokinetics, Incorporated Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 09:00 AM
Mizuho Securities Adjusts Price Target on Cytokinetics to $99 From $103, Maintains Buy Rating MT
Transcript : Cytokinetics, Incorporated, Q4 2023 Earnings Call, Feb 27, 2024
Cytokinetics Q4 Net Loss Narrows, Revenue Decreases; 2024 Outlook Issued MT
Earnings Flash (CYTK) CYTOKINETICS INCORPORATED Reports Q4 Revenue $1.7M, vs. Street Est of $13.3M MT
Cytokinetics, Incorporated Provides Revenue Guidance for 2024 CI
Cytokinetics, Incorporated Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Cytokinetics, Incorporated Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Cytokinetics Insider Sold Shares Worth $960,625, According to a Recent SEC Filing MT
Cytokinetics Insider Sold Shares Worth $2,585,497, According to a Recent SEC Filing MT
Cytokinetics Insider Sold Shares Worth $994,625, According to a Recent SEC Filing MT
Cytokinetics, Incorporated Announces Resignation of Ching W. Jaw as Chief Financial Officer, Effective February 23, 2024 CI
Cytokinetics, Incorporated Announces Resignation of Ching W. Jaw, Senior Vice President, Effective February 23, 2024 CI
Cytokinetics Reports 'Favorable Effects' of Aficamten in Hypertrophic Cardiomyopathy Trial MT
UBS Downgrades Cytokinetics to Neutral From Buy, Adjusts Price Target to $92 From $61 MT
Mizuho Securities Boosts Price Target on Cytokinetics to $103 From $80, Keeps Buy Rating MT
Cytokinetics Insider Sold Shares Worth $425,700, According to a Recent SEC Filing MT
Novartis Interest in Cytokinetics Takeover Has Cooled MT
Correction: Market Chatter: Novartis Interest in Cytokinetics Takeover Has Cooled MT
Cytokinetics Shares Slide as Novartis Reportedly Shies Away From Deal DJ
Chart Cytokinetics, Incorporated
More charts
Cytokinetics, Incorporated is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. The Company specializes in muscle biology and the mechanics of muscle performance. It is developing small molecule drug candidates specifically engineered to impact myocardial muscle function and contractility. Its cardiac muscle contractility program is focused on the cardiac sarcomere. Its clinical-stage drug candidates are: aficamten, which is a next-in-class cardiac myosin inhibitor; omecamtiv mecarbil, which is a cardiac myosin activator; CK-586, which is an additional cardiac myosin inhibitor, and CK-136, which is a cardiac troponin activator. CK-586 is designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
70.11 USD
Average target price
92.07 USD
Spread / Average Target
+31.33%
Consensus